FibroGen Inc (FGEN) VP Pat Cotroneo Sells 49,500 Shares of Stock

FibroGen Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 49,500 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $55.96, for a total value of $2,770,020.00. Following the completion of the sale, the vice president now owns 207,392 shares of the company’s stock, valued at approximately $11,605,656.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pat Cotroneo also recently made the following trade(s):

  • On Monday, January 22nd, Pat Cotroneo sold 25,000 shares of FibroGen stock. The stock was sold at an average price of $48.72, for a total value of $1,218,000.00.
  • On Monday, December 11th, Pat Cotroneo sold 2,851 shares of FibroGen stock. The stock was sold at an average price of $46.00, for a total value of $131,146.00.

FibroGen Inc (NASDAQ:FGEN) traded up $0.05 during trading on Friday, hitting $56.50. The stock had a trading volume of 287,366 shares, compared to its average volume of 695,374. FibroGen Inc has a twelve month low of $22.75 and a twelve month high of $63.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. The stock has a market capitalization of $4,640.05, a PE ratio of -27.70 and a beta of 1.74.

Several equities research analysts have recently commented on the company. Mizuho restated a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. ValuEngine cut FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Four investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $65.67.

Several institutional investors have recently added to or reduced their stakes in FGEN. Bank of Montreal Can raised its position in FibroGen by 2,097.2% in the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. raised its position in FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 1,700 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in FibroGen by 41.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 1,147 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares in the last quarter. Institutional investors and hedge funds own 56.78% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/17/fibrogen-inc-fgen-vp-pat-cotroneo-sells-49500-shares-of-stock.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply